• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

弥漫性胆管肿瘤:管理指南

Diffuse bile duct tumors: guidelines for management.

作者信息

Saunders K, Longmire W, Tompkins R, Chavez M, Cates J, Roslyn J

机构信息

Department of Surgery, UCLA School of Medicine 90024.

出版信息

Am Surg. 1991 Dec;57(12):816-20.

PMID:1746801
Abstract

The majority of patients with bile duct cancer have small focal adenocarcinomas localized to the upper, middle, or lower third of the bile duct. In contrast, a small subgroup of patients have been identified with bile duct tumors that are diffuse, involving multiple segments of the extrahepatic biliary tract. Among 186 patients with documented bile duct cancer treated at the UCLA Medical Center between 1954 and 1988, 13 patients (7%) had diffuse lesions. Patients with diffuse tumors had markedly poorer survival rates than did those with focal lesions. As diffuse tumors are not amenable to resection, surgical management consists primarily of establishing suitable biliary drainage. All patients with bile duct cancer should undergo careful intraoperative evaluation to exclude a diffuse lesion before tumor resection.

摘要

大多数胆管癌患者患有局限性小腺癌,局限于胆管的上、中或下三分之一处。相比之下,已确定一小部分患者患有弥漫性胆管肿瘤,累及肝外胆管的多个节段。在1954年至1988年间于加州大学洛杉矶分校医学中心接受治疗的186例有记录的胆管癌患者中,13例(7%)有弥漫性病变。弥漫性肿瘤患者的生存率明显低于局限性病变患者。由于弥漫性肿瘤不适合切除,手术治疗主要包括建立合适的胆道引流。所有胆管癌患者在肿瘤切除前均应进行仔细的术中评估,以排除弥漫性病变。

相似文献

1
Diffuse bile duct tumors: guidelines for management.弥漫性胆管肿瘤:管理指南
Am Surg. 1991 Dec;57(12):816-20.
2
Clinical and pathological features of primary carcinoma of the cystic duct.胆囊管原发性癌的临床及病理特征
J Hepatobiliary Pancreat Surg. 2009;16(1):75-82. doi: 10.1007/s00534-008-0008-z. Epub 2008 Dec 19.
3
[Palliative surgical and endoscopic therapy of malignant bile duct occlusion].恶性胆管梗阻的姑息性外科及内镜治疗
Chirurg. 1994 Oct;65(10):836-48.
4
Papillary carcinoma of the extrahepatic bile duct: characteristic features and implications in surgical treatment.肝外胆管乳头状癌:特征及对手术治疗的意义
J Am Coll Surg. 2003 Mar;196(3):394-401. doi: 10.1016/S1072-7515(02)01664-2.
5
[Carcinoma of the common bile duct].
Chir Ital. 1983 Apr;35(2):180-92.
6
[Carcinoma of the extrahepatic bile duct].[肝外胆管癌]
Zhonghua Zhong Liu Za Zhi. 1988 Jan;10(1):67-9.
7
Diagnostic and surgical features of Klatskin tumors.肝门部胆管癌的诊断与手术特征。
Chir Ital. 1999 Jan-Feb;51(1):1-7.
8
Carcinoma of the extrahepatic bile ducts.肝外胆管癌
Surgery. 1981 Oct;90(4):596-601.
9
The experiences of hilar skeletonization for the treatment of locally advanced proximal bile duct cancer.肝门骨骼化治疗局部进展期肝门部胆管癌的经验
Hepatogastroenterology. 2001 Sep-Oct;48(41):1298-301.
10
Endocrine tumors of the extrahepatic bile ducts. Pathological and clinical aspects, surgical management and outcome.肝外胆管内分泌肿瘤。病理与临床特征、手术治疗及预后
Hepatogastroenterology. 2004 Sep-Oct;51(59):1295-300.

引用本文的文献

1
Surgical management of proximal bile duct cancers.近端胆管癌的外科治疗。
Langenbecks Arch Surg. 2012 Aug;397(6):869-79. doi: 10.1007/s00423-012-0928-6. Epub 2012 Mar 6.
2
The combination of calmodulin antagonists and interferon-gamma induces apoptosis through caspase-dependent and -independent pathways in cholangiocarcinoma cells.钙调蛋白拮抗剂与γ-干扰素联合通过半胱天冬酶依赖和非依赖途径诱导胆管癌细胞凋亡。
Am J Pathol. 2003 Nov;163(5):2053-63. doi: 10.1016/s0002-9440(10)63563-8.
3
Tamoxifen (TMX)/Fas induced growth inhibition of human cholangiocarcinoma (HCC) by gamma interferon (IFN-gamma).
他莫昔芬(TMX)/Fas通过γ干扰素(IFN-γ)诱导人胆管癌(HCC)生长抑制。
Ann Surg. 2002 Jun;235(6):872-8. doi: 10.1097/00000658-200206000-00016.
4
Combined cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases cytotoxicity to cholangiocarcinoma cells.联合胞嘧啶脱氨酶表达、5-氟胞嘧啶暴露和放射治疗可增加对胆管癌细胞的细胞毒性。
J Gastrointest Surg. 1998 May-Jun;2(3):283-91. doi: 10.1016/s1091-255x(98)80024-3.